Public Health Impact of Adjuvanted RSVPreF3 Vaccination Among US Adults Aged ≥60 Years Residing in Long-Term Care Settings

Adults aged ≥60 years and adults with certain health conditions are at increased risk for severe respiratory syncytial virus (RSV) disease, which can have a substantial clinical burden. Residents in long-term care settings often have multiple risk factors, including age ≥60 years, underlying health conditions, and/or frailty, compounding risk for severe RSV disease. This study evaluated the public health impact of adjuvanted RSV prefusion F3 (RSVPreF3) vaccination on averted RSV disease burden.